ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment of CML was revolutionized in 2001 with the development of the small-molecule inhibitor imatinib mesylate (IM) [12], [13], [14], which binds to the BCR-ABL kinase domain and that prevents its ability to phosphorylate target substrates [12], [15].